What You Should Know:
– Tavros Therapeutics, a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities raises $7.5 million in Seed II financing co-led by existing investor Piedmont Capital Investments and new investor KdT Ventures, with participation from Alexandria Venture Investments.
– Tavros launched in 2020 with a $3 million seed financing by Piedmont Capital Investments and a strategic collaboration with Zentalis Pharmaceuticals, Inc. to develop novel targeted small molecule drug candidates.
– Tavros leverages its functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and help clinically position existing and new molecules with biomarker-driven strategies in areas of high unmet clinical need.
